Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aquestive Therapeutics stock | 6.23

Own Aquestive Therapeutics stock in just a few minutes.


Fact checked

Aquestive Therapeutics, Inc is a biotechnology business based in the US. Aquestive Therapeutics shares (AQST) are listed on the NASDAQ and all prices are listed in US Dollars. Aquestive Therapeutics employs 232 staff and has a trailing 12-month revenue of around USD$59.3 million.

How to buy shares in Aquestive Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Aquestive Therapeutics. Find the stock by name or ticker symbol: AQST. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Aquestive Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$6.23, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Aquestive Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Aquestive Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Aquestive Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Aquestive Therapeutics's share price has had significant positive movement.

Its last market close was USD$6.23, which is 32.26% up on its pre-crash value of USD$4.22 and 341.84% up on the lowest point reached during the March crash when the shares fell as low as USD$1.41.

If you had bought USD$1,000 worth of Aquestive Therapeutics shares at the start of February 2020, those shares would have been worth USD$463.28 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,577.19.

Aquestive Therapeutics share price

Use our graph to track the performance of AQST stocks over time.

Aquestive Therapeutics shares at a glance

Information last updated 2020-10-19.
Latest market close USD$6.23
52-week range USD$1.41 - USD$10
50-day moving average USD$6.6771
200-day moving average USD$5.5118
Wall St. target price USD$14.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.605

Buy Aquestive Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aquestive Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aquestive Therapeutics price performance over time

Historical closes compared with the close of $6.23 from 2020-11-16

1 week (2020-11-18) -0.64%
1 month (2020-10-23) 18.44%
3 months (2020-08-25) -22.03%
6 months (2020-05-22) 8.35%
1 year (2019-11-25) -17.37%
2 years (2018-11-23) -38.92%
3 years (2017-11-22) N/A
5 years (2015-11-22) N/A

Aquestive Therapeutics financials

Revenue TTM USD$59.3 million
Gross profit TTM USD$32.2 million
Return on assets TTM -37.7%
Return on equity TTM -3347.45%
Profit margin -84.2%
Book value $-0.985
Market capitalisation USD$169.1 million

TTM: trailing 12 months

Shorting Aquestive Therapeutics shares

There are currently 1.9 million Aquestive Therapeutics shares held short by investors – that's known as Aquestive Therapeutics's "short interest". This figure is 25.1% up from 1.5 million last month.

There are a few different ways that this level of interest in shorting Aquestive Therapeutics shares can be evaluated.

Aquestive Therapeutics's "short interest ratio" (SIR)

Aquestive Therapeutics's "short interest ratio" (SIR) is the quantity of Aquestive Therapeutics shares currently shorted divided by the average quantity of Aquestive Therapeutics shares traded daily (recently around 1.6 million). Aquestive Therapeutics's SIR currently stands at 1.19. In other words for every 100,000 Aquestive Therapeutics shares traded daily on the market, roughly 1190 shares are currently held short.

However Aquestive Therapeutics's short interest can also be evaluated against the total number of Aquestive Therapeutics shares, or, against the total number of tradable Aquestive Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aquestive Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Aquestive Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0964% of the tradable shares (for every 100,000 tradable Aquestive Therapeutics shares, roughly 96 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aquestive Therapeutics.

Find out more about how you can short Aquestive Therapeutics stock.

Aquestive Therapeutics share dividends

We're not expecting Aquestive Therapeutics to pay a dividend over the next 12 months.

Aquestive Therapeutics share price volatility

Over the last 12 months, Aquestive Therapeutics's shares have ranged in value from as little as $1.41 up to $10. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aquestive Therapeutics's is 3.8483. This would suggest that Aquestive Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Aquestive Therapeutics overview

Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The company's proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly and neuroendocrine tumors. It also develops AQST-119, an oral soluble film formulation of tadalafil for the treatment of erectile dysfunction; and APL-130277, a sublingual film using apomorphine to treat parkinson's disease. Aquestive Therapeutics, Inc. was founded in 2004 and is headquartered in Warren, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site